{
    "prompt": "\n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: \n    The following is a summarized molecular profile from MSK-IMPACT.\n    Based on this profile, answer with the appropriate treatments for this patient in the format above.\n    Patient ID: P-0003634\nAge: 59\nGender: Female\nSample ID: P-0003634-T01-IM5\nGene Panel: IMPACT410\nCancer Type: Breast Invasive Ductal Carcinoma\nSample Type: Metastasis\nTumor Purity: 90.0%\n=============\nDNA Variants:\nESR1 c.1613A>G (p.D538G) - in 41.00% of 351 reads\nFOXP1 c.1495_1520del (p.F499Hfs*9) - in 28.00% of 599 reads\nCNA Data:\nPIK3C2G - High Level Amplification\nMDM2 - High Level Amplification\nFGFR1 - High Level Amplification\nMAP2K4 - Homozygous Deletion\nKRAS - High Level Amplification\nETV6 - High Level Amplification\nStructural Variants:\nNo structural variant data found.\n    ",
    "response": "{\n  \"Status\": \"no_match\",\n  \"Message\": \"No drugs are FDA-approved for the provided context\"\n}"
}